LeMaitre Vascular, Inc. has reported its financial results for the third quarter of 2026, showcasing a significant 11% increase in sales compared to the same period last year. The company also announced a quarterly dividend of $0.25 per share, reflecting its commitment to returning value to shareholders. This performance is particularly noteworthy as it highlights the company's resilience and growth potential in the competitive landscape of vascular devices and surgical instruments.

Founded in 1983, LeMaitre Vascular, Inc. operates under the SIC code 3841, which covers Surgical & Medical Instruments & Apparatus. The company trades on the Nasdaq under the ticker symbol LMAT. As a large accelerated filer, LeMaitre is subject to rigorous reporting requirements and has consistently provided updates on its financial health and operational strategies.

According to the recent SEC filing dated November 4, 2026, LeMaitre's preliminary financial results for Q3 2026 indicate sales of $68 million, which includes a 12% organic growth rate. The gross margin stood at 71.7%, although it experienced a 360 basis point decline compared to the previous year. Operating expenses rose by 21%, reflecting the company's investment in growth and operational efficiency.

The filing also detailed that LeMaitre's operating income for the quarter was $17.7 million, a decrease of 13% year-over-year, while earnings per share (EPS) were reported at $0.65, down 14% from Q3 2025. However, the company noted a sequential cash increase of $13.5 million, bringing its total cash reserves to $390 million as of September 30, 2026.

LeMaitre's growth was driven by strong sales in grafts and shunts, with respective increases of 20% and 14%. The company also highlighted a successful international launch of its Artegraft product, which contributed to an 18% increase in sales. The company's operations in the EMEA region grew by 18%, while the Americas and APAC regions saw increases of 9% and 5%, respectively.

In a strategic move, LeMaitre acquired certain vascular assets from B. Braun for $19.2 million. These assets, which include polyester and silver-coated grafts, are expected to enhance LeMaitre's product portfolio and strengthen its market position. The sales from these assets recorded $9.4 million in 2025 and will transition into LeMaitre’s distribution channels over the next 18 to 24 months.

Looking ahead, Chairman and CEO George LeMaitre expressed optimism about the company's future, stating, "We expect 2026 to be another year of healthy sales (+11%) and EPS growth (+18%). Biologics continue to drive sales due to Artegraft’s international launch and the continued growth of RestoreFlow Allografts. The acquired B. Braun products will strengthen our core vascular portfolio while leveraging our expanding 31-country sales force." This outlook suggests that LeMaitre is well-positioned to capitalize on emerging opportunities in the surgical and medical instruments sector.

As the company continues to navigate the complexities of the medical device industry, its recent performance and strategic acquisitions may influence competitors and shape market dynamics. The filing does not specify what happens next, but it is clear that LeMaitre Vascular is focused on growth and enhancing shareholder value.